Do you know which biologic therapies are most helpful for your patients with inflammatory bowel disease (IBD)? IBD plagues three million Americans and is common enough of a condition that you need to understand all the available therapeutic options, how they impact patients and what factors should determine which therapy will work best. In response to a learning need advanced practice providers (APPs) have cited, AGA has launched APP Pharmacology: IBD Series – Biologics, a free course, which provides detailed insights on pharmacological therapies for:
- TNF antagonist (anti-TNF).
- Anti-integrin.
- Interleukin.
- Janus Kinase (JAK) inhibitor.
Leading APPs, Kimberly Kearns, MS, ANP-BC, Erin Darguzas, MSN, APN, Heidi Drescher, RD, MMS, PA-C, and Erica Heagy, MSN, FNP, CNS, will guide you on your journey for determining the best biologic therapies for patients. The course will also cover the implications of COVID-19 on IBD and review current treatment guidelines. Begin learning now.
This program was supported by independent educational grants from Gilead Sciences, Inc. and Takeda Pharmaceuticals U.S.A., Inc.
